Alterations of TP53 were reported to be gained at relapse in 54% of 23 ALL samples and found to predict chemotherapy resistance and poor outcome in first relapse of childhood B-cell-precursor ALL.10 In T-ALL, TP53 mutations were previously detected in first relapse in 12 of 51 patients (24%).9 Patients with TP53 mutations in leukemic samples experienced a shorter duration of survival and were significantly less likely to have achieved a complete second remission than patients without TP53 mutations.9 Our results confirm and extend these earlier findings. Here, TP53 is linked to acute lymphoblastic leukemia.